Ascentage Pharma’s Promising Study on Lisaftoclax for CLL/SLL: A Potential Game-Changer?

Ascentage Pharma Group International ((HK:6855)) announced an update on their ongoing clinical study.

Study Overview: Ascentage Pharma Group International is conducting a Phase Ib study titled APG-2575CU101, A Phase Ib Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). The study aims to assess the safety and tolerability of lisaftoclax, identify dose-limiting toxicities, and determine the maximum tolerated dose or recommended phase 2 dose. This research is significant as it targets CLL/SLL, conditions with limited treatment options.

Intervention/Treatment: The study tests lisaftoclax, an experimental drug administered in ramp-up doses ranging from 400mg to 1000mg. The purpose is to evaluate its efficacy and safety in treating CLL/SLL.

Study Design: This interventional study uses a non-randomized, parallel assignment model with no masking. The primary purpose is treatment, focusing on dose escalation using a standard 3+3 design, where doses are increased in cohorts to determine safety and efficacy.

Study Timeline: The study began on December 30, 2019, with the latest update submitted on April 8, 2025. These dates are crucial as they indicate the study’s progression and ongoing nature, providing investors with a timeline for potential results and impacts.

Market Implications: The ongoing study of lisaftoclax by Ascentage Pharma could influence the company’s stock performance positively if successful, given the high demand for effective CLL/SLL treatments. Investors should monitor this study’s updates, as positive results could enhance Ascentage’s market position and investor sentiment, especially in comparison to competitors in the oncology sector.

The study is currently recruiting, with further details available on the ClinicalTrials portal.